Importantly, SIRT1 inhibition had less of an effect on proliferation and apoptosis of normal CD34+ cells, suggesting that SIRT1 might be a new target for eliminating CML cancer stem cells. Here, SIRT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.